Bern researcher viewing sample)

Research & Development

Innovation is in Our DNA

Innovation is in our DNA and is the core of everything we do at CSL Behring. Our team of over 1,400 R&D experts are dedicated to developing and delivering new therapies to solve unmet medical needs and save lives. We have created one of the largest and most efficient plasma collection networks in the world and strive to be the best at delivering safe and effective medicines for our patients.

  • Approx. 10.5%

    of global revenue was invested in R&D in 2016/17

  • US$2.6 billion

    in R&D investments in last 5 years (incl. Seqirus)

  • >1,400

    research & development employees

Gloved hands on lab beaker

Investment in our R&D

Investment in R&D is an important driver for CSL Behring’s future growth. We have a high quality and potentially valuable portfolio of projects in various stages of development. We continue to make a balanced investment in the life cycle management and market development of existing products that bring short to mid-term commercial benefits, and we make strategic investments in longer term, higher risk and high opportunity new product development activities.

Current Clinical Trials

Therapeutic Area Condition Description
Bleeding Disorders
Hemophilia A An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Congenital Fibrinogen Deficiency An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Learn More
Von Willebrand Study of Voncento® in Subjects With Von Willebrand Disease Learn More
Hemophilia B
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Learn More
Immune Deficiencies Primary Immune Deficiency (PID) Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) Learn More
Primary Immune Deficiency (PID) Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Learn More
Therapeutic Proteins Other Inflammatory or immune system disorders Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More
Antibody-mediated kidney transplant rejection Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More

World-Class R&D Network

CSL is a global specialty biotech with a strong commitment to funding research and development of medicines to support its continued growth. We operate as one integrated global research and development organization that assembles coordinated global project teams, drawing together staff from different countries depending on their expertise. Our teams rely on a project management framework that facilitates collaboration across national and cultural boundaries.

CSL Parkville office

CSL Limited
Global Corporate HQ
R&D and Manufacturing

CSL Behring
R&D and Manufacturing

Bio21 Global Research and Translational Medicine Hub

Marburg employees

CSL Behring
R&D and Manufacturing

Kankakee office
United States

CSL Behring
Head Office and R&D

CSL Behring
R&D and Manufacturing


Bern, Switzerland

CSL Behring
R&D and Manufacturing

Researchers taking notes

CSL Behring

Asian male and caucasian female in a lab

R&D and Manufacturing

R&D Briefings Archives

R&D Briefing December 2017 pdf
R&D Briefing December 2016 pdf
R&D Briefing December 2015 pdf
R&D Briefing December 2014 pdf
Product Pipeline

Innovation is in our DNA; Learn more about what's in our pipeline.

Learn More
Clinical Trials

Find out how to participate.

Learn More
Job Opportunities

Join us and make history with the brightest, most passionate people from every discipline.

Learn More

Get our latest news in your inbox
First name
Last name


You have now been added
to the CSL Behring news list